CSPC’s monthly weight-loss shot advances to US trials
CSPC’s SYH2082, a once-monthly GLP-1/GIP co-agonist, won FDA clearance to begin US clinical trials in adults with obesity and weight-related conditions, offering a potential monthly alternative to weekly GLP-1 therapies with implications for long-term metabolic health and investor interest.
Why it mattersFDA clearance for SYH2082's US trial requires reallocating capital toward monthly GLP-1/GIP candidates.